Functional Dyspepsia Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034

The Functional Dyspepsia market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Daewoong Pharmaceutical Co Ltd, ISOThrive Inc, Mitsubishi Tanabe Pharma Corp, RaQualia Pharma Inc,Renexxion LLC, Zeria Pharmaceutical Co Ltd., GlaxoSmithKline, Abbott, Dexa Medica Group, Astellas Pharma Inc, Eisai Co., Ltd., Forest Laboratories, Novartis, Bayer

[Nevada, United States] - DelveInsight's "Functional Dyspepsia Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Functional Dyspepsia, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Functional Dyspepsia Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/sample-request/functional-dyspepsia-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Functional Dyspepsia Market Report:
• The Functional Dyspepsia market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).
• In June, 2024: Dexa Medica Group announced a 2-arm, prospective, double-blind, randomized and placebo-controlled study using DLBS2411 at a dose of 250 mg twice daily (before morning and evening meals), for a 4-week course of therapy, for the treatment of patients with functional dyspepsia (FD), and an additional 8 weeks after end of therapy (Week 12) for follow-up visit.
• In June, 2024: Zeria Pharmaceutical announced that this study is to evaluate pharmacokinetics, efficacy and safety of Z-338 of pediatric patients with functional dyspepsia (FD).
• In April, 2024: Abbott announced a muti-national study, in subjects with functional dyspepsia. The study will screen approximately 700 subjects and include 564 subjects
• In April, 2024: Lallemand Health Solutions announced that their study aims to evaluate the efficacy of Lacidofil® STRONG as an adjuvant therapy to a standard 14-day H. pylori eradication treatment among H. pylori-positive participants with non-ulcer dyspepsia.
• Functional Dyspepsia is more prevalent in women compared to men, attributed to sex-specific differences in gastrointestinal function, including variations in hormone mechanisms, pain signaling, and healthcare utilization.
• Currently, the only approved drug specifically for functional dyspepsia is ACOFIDE (Acotiamide), developed by Astellas Pharma and Zeria Pharmaceuticals, and approved exclusively in Japan.
• Key Functional Dyspepsia Companies are as follows: Daewoong Pharmaceutical Co Ltd, ISOThrive Inc, Mitsubishi Tanabe Pharma Corp, RaQualia Pharma Inc,Renexxion LLC, Zeria Pharmaceutical Co Ltd., GlaxoSmithKline, Abbott, Dexa Medica Group, Astellas Pharma Inc, Eisai Co., Ltd., Forest Laboratories, Novartis, Bayer
• Key Functional Dyspepsia Therapies are as follow: GW679769, Itopride Hydrochloride 150 mg, DLBS2411, YM443, Acotiamide hydrochloride hydrate, UI05MSP015CT, DWJ1252, Gasmotin, Rabeprazole, Imonogas, Espumisan, Motiliton, Pantoline, Domperidone, Itopride Hydrochloride, Cinitapride, domperidone, Tegaserod, STW5
• Launching multiple stage Functional Dyspepsia pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Functional Dyspepsia market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/report-store/functional-dyspepsia-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Functional Dyspepsia Overview:
Functional dyspepsia (FD) is a chronic disorder of sensation and movement (peristalsis) in the upper digestive tract. It is characterized by symptoms such as upper abdominal discomfort, bloating, early satiety, and nausea. Despite its prevalence, FD remains a condition with unmet therapeutic needs. Here is an updated overview of drug uptake, market insights, epidemiology, and the market drivers and barriers.

Functional Dyspepsia Epidemiology Segmentation:
The Functional Dyspepsia market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Functional Dyspepsia Total Prevalence
• Functional Dyspepsia Prevalent Cases by severity
• Functional Dyspepsia Gender-specific Prevalence
• Functional Dyspepsia Diagnosed Cases of Episodic and Chronic

For more information about Functional Dyspepsia companies working in the treatment market, visit https://www.delveinsight.com/sample-request/functional-dyspepsia-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Functional Dyspepsia Market Insights
• There is a growing demand for therapies that address the underlying pathophysiology of FD, including impaired gastric accommodation, delayed gastric emptying, and visceral hypersensitivity. Novel treatments like acotiamide and relamorelin that specifically target gastric motility and hypersensitivity are gaining attention in the market.
• Despite the availability of various symptomatic treatments, there is still a significant unmet need for therapies that provide comprehensive relief from FD symptoms.
• The market landscape for FD treatments varies significantly by region. In Japan, for example, acotiamide has been widely adopted, while in Europe and North America, acid suppressants and antidepressants dominate.

Functional Dyspepsia Drugs Uptake
• Prokinetic drugs, such as metoclopramide and domperidone, are commonly used to manage FD symptoms by improving gastric motility. However, the uptake of these drugs has been limited by concerns about side effects, particularly related to long-term use, including tardive dyskinesia and cardiac issues.
• Proton pump inhibitors (PPIs), like omeprazole and lansoprazole, and H2 receptor antagonists (ranitidine, famotidine) are often prescribed for FD, particularly in cases associated with acid-related symptoms.
• Low-dose antidepressants, such as amitriptyline and mirtazapine, are increasingly being used to treat FD, particularly in patients with overlapping psychological symptoms like anxiety and depression.
• Several new drugs are under investigation for FD. For example, acotiamide, a prokinetic drug that modulates gastric motility, has been approved in Japan and is showing potential in other markets.

Dive into our comprehensive market research report to discover in-depth insights, emerging trends, and strategic opportunities @ https://www.delveinsight.com/sample-request/functional-dyspepsia-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Functional Dyspepsia Therapies and Key Companies:
• GW679769: GlaxoSmithKline
• Itopride Hydrochloride 150 mg: Abbott
• DLBS2411: Dexa Medica Group
• YM443: Astellas Pharma Inc
• Acotiamide hydrochloride hydrate: Zeria Pharmaceutical
• UI05MSP015CT: Korea United Pharm. Inc.
• DWJ1252, Gasmotin: Daewoong Pharmaceutical Co. LTD.
• Rabeprazole: Eisai Co., Ltd.
• Imonogas, Espumisan: Johnson & Johnson
• Motilitone, Pantoline: Dong-A ST Co., Ltd.
• Domperidone: Xian-Janssen Pharmaceutical Ltd.
• Itopride Hydrochloride :Forest Laboratories
• Cinitapride, domperidone: Eisai China Inc.
• Tegaserod: Novartis
• STW5: Bayer

Functional Dyspepsia Epidemiology:
Functional dyspepsia is a common condition, affecting approximately 10-20% of the global population. The prevalence tends to be higher in developed countries, where lifestyle factors, such as poor diet and stress, contribute to gastrointestinal disorders. It affects both men and women, though women tend to report symptoms more frequently.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/functional-dyspepsia-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Functional Dyspepsia Market Drivers:
• Increasing Prevalence of Gastrointestinal Disorders
• Advancements in Gastrointestinal Diagnostics
• Growing Interest in Patient-Centric Treatments
• Increasing R&D and Clinical Trials

Functional Dyspepsia Market Barriers:
• Complex Pathophysiology of FD
• High Cost of Novel Therapies
• Side Effects of Current Medications

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/functional-dyspepsia-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Functional Dyspepsia Market Report:
• Study Period: 2020-2034
• Coverage: 7MM (The United States, EU5, and Japan)
• Key Functional Dyspepsia Companies: Daewoong Pharmaceutical Co Ltd, ISOThrive Inc, Mitsubishi Tanabe Pharma Corp, RaQualia Pharma Inc,Renexxion LLC, Zeria Pharmaceutical Co Ltd., GlaxoSmithKline, Abbott, Dexa Medica Group, Astellas Pharma Inc, Eisai Co., Ltd., Forest Laboratories, Novartis, Bayer
• Key Functional Dyspepsia Therapies: GW679769, Itopride Hydrochloride 150 mg, DLBS2411, YM443, Acotiamide hydrochloride hydrate, UI05MSP015CT, DWJ1252, Gasmotin, Rabeprazole, Imonogas, Espumisan, Motiliton, Pantoline, Domperidone, Itopride Hydrochloride, Cinitapride, domperidone, Tegaserod, STW5
• Functional Dyspepsia Therapeutic Assessment: Current marketed and emerging therapies
• Functional Dyspepsia Market Dynamics: Functional Dyspepsia Market drivers and Functional Dyspepsia barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Functional Dyspepsia Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Functional Dyspepsia market outlook, drug uptake, treatment scenario, and epidemiology trends, https://www.delveinsight.com/sample-request/functional-dyspepsia-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1. Key Insights
2. Report Introduction
3. Executive Summary of Functional Dyspepsia
4. Key Events
5. Functional Dyspepsia Epidemiology and Market Forecast Methodology
6. Functional Dyspepsia Market Overview at a Glance
7. Disease Background and Overview: Functional Dyspepsia
8. Treatment and Management
9. Epidemiology and Patient Population of Functional Dyspepsia in the 7MM
10. Patient Journey
11. Key Endpoints in Functional Dyspepsia
12. Marketed Therapies
13. Functional Dyspepsia: Seven Major Market Analysis
14. Unmet Needs
15. SWOT Analysis
16. KOL Views
17. Market Access and Reimbursement
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.